Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study
尼洛替尼与达沙替尼在初诊慢性粒细胞白血病患者中达到MR4.5的疗效比较:JALSG CML212随机研究
期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2024012655
Matsumura, Itaru; Ohtake, Shigeki; Atsuta, Yoshiko; Kurata, Mio; Minami, Yosuke; Takahashi, Naoto; Nakaseko, Chiaki; Iriyama, Noriyoshi; Fujimaki, Katsumichi; Kakihana, Kazuhiko; Ogasawara, Yoji; Ono, Takaaki; Okada, Masaya; Tauchi, Tetsuzo; Miyamoto, Toshihiro; Ohnishi, Kazunori; Sakaida, Emiko; Fujisawa, Shin; Kobayashi, Yukio; Asou, Norio; Naoe, Tomoki; Kiyoi, Hitoshi; Miyazaki, Yasushi